CC BY
33
Клиникалық жағдай/Клинический случай/Case report
Материал поступил в редакцию: 16-02-2015 Материал принят к печати: 27-03-2015 УДК 616-002.77
The case report of multiple myeloma and symmetric seronegative polyarthritis
Tuba ТШау Koca
Malatya State Hospital, Physical Medicine and Rehabilitation Clinic, Turkey
Multiple Myeloma (MM) is a malignant proliferation of plasma cells producing monoclonal proteins. MM may manifest as skeletal pain, pathological fractures, fatigue, anemia, infection, hypocalsemia, spinal cord compression or renal failure. Proliferating plasma cells are responsible for these clinical symptoms. Seronegative erosive poly/olygoarthritis may be observed in patients with MM and other monoclonal gammopathies concurrently at the time of diagnosis, after the diagnosis or occasionally before it.
The patient admitted to hospital in May 2012 with the complaint of fatigue, polyarthralgia, limitation of hand joints’ movements. Her physical examination revealed flexion contractures in elbows, fingers, knee, feet joints bilaterally. Laboratory examination revealed a sedimentation rate of 106 mm/h; rheumatoid factor (RF), C-reactive protein (CRP) and anti-cyclic citrullinated peptide (anti-CCP) was negative and anti nuclear antibody (ANA) tested by immunfluorescence technique was positive. The patient is considered and followed up as an inflammatory arthritis developed in MM process. The joint involvements were symmetric, erosive pattern and seronegative tested. The diseases with monoclonal gammopathies may lead to erosive polyarthritis or olygoarthritis so we should investigate the immunopathogenesis of arthritis process.
Keywords: Multiple myeloma - seronegative polyarthritis - plasma cell dyscrasia.
J Clin Med Kaz 2015; 2(36): 34-38
Correspondence Author: Tuba TUlay Koca, MD, Malatya State Hospital, Physical Medicine and Rehabilitation Clinic, Turkey.
Phone: +90 422 212 1028/ 0506 3819295, E-mail: [email protected].
ТАРАЛҒАН МИЕЛОМА МЕН СИММЕТРИЯЛЫҚ СЕРОНЕГАТИВТІ БУЫН ҚАБЫНУЫНЬЩ КЛИНИКАЛЫҚ ЖАҒДАЙЫ Tuba Tulay Koca
Малатья қаласындағы мемлекеттік аурухана, физикалық медицина мен қалпына келтіру клиникасы, Малатья, Түркия
Таралған миеломалар (ТМ) - моноклоналды ақуыздарды бөліп шығаратын қан сарысуы жасушаларының қатерлі көбеюі. ТМ клиникалық көріністері көп, ол буындардағы ауырсыну синдромымен, патологиялық сүйек сынуымен, шаршаңдықпен, қаназдықмен, әр түрлі жұқпалармен, гипокальциемиямен, жұлын компрессиясымен және бүйрек жетіспеушілігімен көрініс табады. Бұл клиникалық белгілердің пай-да болуына қан сарысуының пролиферацияланған жасушалары жауап береді. Сонымен бірге ТМ бар науқастарда серонегативті эрозиялық поли/олигоартрит байқалуы мүмкін.
Біздің науқасымыз 2012 жылдың мамыр айында ауруханаға шаршаңдық, полиартральгия, саусақ буындарының қимыл қозғалысының шектелуі секілді шағымдармен түскен болатын. Физикалық тексеру кезінде науқаста шынтақ, тізе, қол мен аяқтың саусақ буындарының екіжақты контрактурасының бар екені байқалды. Зертханалық тексерулер барысында ЭТЖ-ның 106 мм/сағ. дейін жоғарылағандығы және ревматоидты фактор, С-реактивті ақуыз, анти-КПК көрсеткіштерінің теріс, ал АНА көрсеткішінің оң екендігі анықталды. Бұл жағдай ТМ нәтижесінде болған артрит ретінде қарастырылды. Буындардағы эрозиялық зақымданулар симметриялық түрде болды. Моноклоналды гам-мапатиялармен болатын аурулар серонегативті эрозиялық поли/олигоартриттерге әкелуі мүмкін. Сондықтан буын қабынуының иммуногенезін зерттеген жөн.
Маңызды сөздер: таралған миелома - серонегативті полиартрит - қан сарысуы жасушаларының дискразиясы.
КЛИНИЧЕСКИЙ СЛУЧАЙ МНОЖЕСТВЕННОЙ МИЕЛОМЫ И СИММЕТРИЧНОГО СЕРОНЕГАТИВНОГО
ПОЛИАРТРИТА
Tuba Tulay Koca
Государственная больница в г Малатья, клиника физической медицины и реабилитации, Турция
Множественной миеломы (ММ) - это злокачественное размножение плазматических клеток, продуцирующих моноклональные белки. Клинически ММ может проявляться суставным болевым синдромом, патологическими переломами, усталостью, анемией, инфекциями, гипокальциемией, компрессией спинного мозга или почечной недостаточностью. За эти клинические симптомы отвечают пролиферирующие плазменные клетки. Также у пациентов с ММ может наблюдаться серонегативный эрозивный поли/олигоартрит.
Наш пациент госпитализирован в мае 2012 года с жалобами на усталость, полиартралгию, ограничение движений в суставах кистей рук. При физическом осмотре выявлены двухсторонние контрактуры локтевых, коленных суставов, кистей рук и ног. Лабораторные исследования показали следующие данные: СОЭ - 106 мм/ч; ревматоидный фактор, С-реактивный белок и анти-КПК были отрицательными, АНА были положительными. Данный случай рассматривался как воспалительный артрит вследствие ММ. Эрозивные поражения суставов были симметричными. Заболевания с моноклональными гаммапатиями могут привести к серонегативным эрозивным поли/олигоартритам. Поэтому необходимо исследовать иммунопатогенез артрита.
Ключевые слова: Множественная миелома - серонегативный полиартрит - дискразия плазматических клеток.
34
№2 (36) 2015 Clinical Medicine of Kazakhstan
Introduction
Multiple myelom (MM) is malign proliferation of the plasma cells that produce monoclonal protein. It forms 10% of all hematological malignities. It is the most common malign neoplasm of the bone narrow. Besides its clinical signs as bone pain, pathological fractures, asthenia, anemia, infection (mostly pneumococcal), hypocalcemia, spinal cord injury or renal impairment, it is generally diagnosed with blood examinations done for unrelated problems. The plasma cell proliferation that increases in bone marrow is responsible of the clinic signs. 1/3 of the patients are diagnosed after pathological fracture. 2/3 of the patients complain about bone pain. Nonspecific constitutional complaints caused by hyperviscosity and hypercalcemia may be seen. Lumbago, weakness and sense disorder in extremities should be warning for spinal cord injury. Spinal cord injury may be related to plasmocytoma or vertebrae pathologic fracture.
For diagnosis, 10% and above monoclonal plasma cell increase in bone marrow or/else end organ injury associated plasmocytoma and underlying plasma cell disorders are needed. Final diagnosis is done with biopsy of bone marrow and serum
protein electrophoresis.
Our case showed erosive arthritis clinic in symmetric seronegative pattern with MM. We examined the relation between these two clinic entities with literature review.
Case
В Our case appealed on May 2012 with complaints of asthenia, artralgia, limitation of movement on hand joints. In 2003, She was diagnosed with MM at outer center, with complaints of asthenia and anorexia. In her history; we learned that in 2010, arthritis had developed on hand, wrist and elbow joints bilaterally; similar complaints had developed on feet, ankle and knee joints 3 months before she comes here. In 2010 the patient was started to zolendronic acid treatment for 6 months. Increase in thoracic kyphosis and costocondral sensitivity was existing in locomotor system examination. Flexion contracture was diagnosed in both elbows and hand joints.
There was limitation of movement in patient’s both hands, wrists, elbows, knees and feet with soft tissue hypertrophy. She has no nail and skin symptoms. (Image 1,2,3,4).
Image 1- Both hands and wrist
Image 2- Flexion contracture in left elbow
Image 3- Hypertrophy of soft tissue in both knees Image 4- Hypertrophy of soft tissue in both ankles
In conventional radiographies; we diagnosed cortical narrowing in interarticular space. Loss of length in thoracic erosions in hand metacarpophalangeal (MCP) joints, proximal vertebrae in spinal graphy and locally osteolythic lesions showed interphalangeal (PIP) joints and intercarpal joints and symmetric in pelvic graphy is showed (Image 1,2,3,4).
№2 (36) 2015 Clinical Medicine of Kazakhstan
35
Image 1- Anteroposterior view of hand and wrist:
symmetric intraarticular narrowing and local cortical erosions are seen in intercarpal joints and MCP, PIP
Image 2- Anteroposterior view of shoulder: no lesion seen in clavicule and humerus bones
Image 3- - Lateral view of thoracolomber: loss of lengt in vertebrae and kyphosis is seen
Image 4 - Anteroposterior view of pelvis: lythic lesions are observed in iliac crest
There was normocrom normociter anemia (Hb:9.7 gr/ dl, MCV:89.9), increase of blood urea (BUN):64 mg/dl (1050) and reverse in albumin/globulin ratio with laboratory examination(alb:3.6 g/dl, glob:4.8 g/dl).
While romatoid factor (RF) and C-reactive protein (CRP) value is negative in the serologic evaluation, sedimentation value is measured as: 106 mm/h. In urinalysis.30gr/dl protein is found. While anti- CCP value is negative, anti-nuclear antibody (ANA) value that is examined with immunfluoroscent technic is two positive tested. Synovial membrane analyse couldn’t be practised because the patient hasn’t active arthrit. All examined abdomen ultrasonography (USG) is normal. With the measurement of spinal DEXA (dual X-ray absorbsiometer) total t score:-2.6, z score:-0.5 with osteopenia is determined.
Our patient is evaluated as inflammatory joint disease that developped in MM process. Joint involvement is erosive and seronegative. It is very similar to rheumatoid arthrit (RA) clinic. Negativity of anti-CCP and RF, absence of rheumatoid nodule despite erosive progress we excluded RA. Even tenosynovit in hand finger flexor tendon and PIP, MKP joints limitation of movement seemed like sclerodactily in clinic; there was no skin thickening in hand and face of the patient also there was no brown pigmented lesions, this is why we excluded scleroderma, oftenly with raynould phenomenon characterized, as our prediagnosis. Likewise there was no internal organ involvement.
We examined the patient in the aspects of other connective
tissue diseases that may cause inflammatory arthrit (Sjogren syndrome, polymyozitis, systemic lupus eritematozus etc...). We also examined our patient in terms of other destructive joint pathologies. There seen locally osteolythic lesions. We didn’t determine lythic or sclerothic lesion in long bones (humerus and femur). No focal symptom associate to spinal cord injury was found in the neurologic examination. No destructive vertebral pathology was seen in the conventional radiographies. We gave our patient TENS (transcutaneous electrical nerve stimulation) and exercise program for joint movement limitations and pain treatment. We provide vertebral steel balen corset and double canedien support to prevent pathologic fractures. Patient’s pain decreased from 8 cm to 4 cm according to VAS (visual analogue scala). We thought that immunogenetic process of MM can active inflammatory synovitis cascade.
Discussion
HBesides clinical signs in MM like pathological fractures, bone pain, fatigue, anemia, infection (especially pnomococal), hypocalcemia, spinal cord compression or renal insufficiency may be revealed; it is usually determined randomly. Patients can refer to clinic with the complaints of nonspesific constituonal symptoms cause of hyperviscosity and hypercalcemia. Low back pain, weakness and numbness of the extremities should be warning in terms of spinal cord compression. Spinal cord compression may lead to pathological fractures of the vertebrae
36
№2 (36) 2015 Clinical Medicine of Kazakhstan
or plasmocytoma. Such neurologic findings; carpal tunnel syndrome, meningitis, peripheral neuropathy may rarely seen in clinic process.
Pathological fractures and sensitivity of bones due to focal lytic lesions are oftenly seen. Typical radiological appearance is lytic lesions. The other types of bone lesions include changes in sclerotic, porotik and rarely (3%) lythic-sclerotic pattern. Extrameduller plasmocytoma (soft tissue masses consisting of plasma cells) can be seen all over the body. Also, hepatosplenomegaly and cardiomegaly can be seen. In some cases, amyloidosis may contribute toclinic. The physical signs due to amyloidosis are bilateral swelling of shoulders, makroglossus, skin lesions, peripalpebral purpura etc... [2]. MM rarely comes with signs of arthritis. In cases related to arthritis associated with monoclonal gammopaties, joint involvement develops simultanously or a period of time after diagnosis. Arthritis pattern is, similar to RA, symmetric polyarthritis or olygoartrit; unlike RF is negatively tested.
Three pathogenetic pathways can cause joints symptoms of MM. These are erosive arthritis caused by malignant plasmocytes; arthritis or trap neuropathies caused by precipating paraproteins or amyloid proteins. It is observed that paraproteins that cause arthrit clinic are frequently in monoclonal pattern [3,4].
in patients with MGUS (unknown-featured monoclonal gammopaties) arthritis are seen in both sexes equally and RF tested negatively. Also, in cells lead to arthritis, there was no heavy chains detected, besides 89% light chain kappa have been identified [5,6]. In arthritis process it was thought that kryopresipitat paraproteins activate inflammatory cascade in synovial fluid by crystallization [7,8].
In addition, amyloid proteins in plasma cells dyscrasia are also, similar to paraprotein kyropresipitat in synovium, can cause carpal tunnel syndrome by accumulinating.
AL amyloidosis that seen in MM can cause joint involvement similar to RA. It is find out that symptoms in acute phase responses are similar to RA while RF is negatively tested. In chronic polyarthralgia systemic AL amyloidosis is an important differential diagnosis. Rarely, plasma cell discrasia may bring up with atypical joint involvement. Therefore, by immunohistochemically and cytogenetically plasma cell dyscrasia should be investigated in patients come with atypical
artrit clinic elderly [9,10].
Result of studies, arthrit clinic has been regressed with the chemotherapeutic agents we give in MM treatment. Bisphosphonates that is given to prevent MM and skeletal complications in solid bone tumors are useful. Zolendronik acid is a bisphosphonate commonly used for this purpose. It is revealed that the zolendronic acid treatment is useful for pathologic fracture, cord conpression and mortality. Especially when the treatment lasts for 18 months [11,12].
It should be kept in mind that MM disease can be seen as comorbid in patients with RA. B cell discrasia may occur at 3.8% frequency in long-term RA patients. But these cases are long- termed (at least 10 years) and RF positively tested. IL-6 cytokine plays an important role in terms of patogenetic in both cases. This is why Tocilizumab treatment can be useful in these cases existing togetherly [13].
In literature examination some MM cases show symptoms similar to scleroderma in atypic pattern. It is thought that processes associated with MM may cause scleroderma-like lesions. Fibroblast activation that cause tissue fibrosis in related organs plays a role in scleroderma pathogenesis. Immune system activation associated with endothelial cell apoptosis, dysfunction and activation of fibroblasts result skin and internal organ fibrosis. Fibrotic process is sustained autonomous autocrine by activated fibroblasts. Raynould phenomenon is the earliest symptom in systemic sclerosis. Musculoskeletal symptoms are oftenly seen. Early symptoms include arthralgia, myalgia and in some patients inflammatory artropathy may occur. The most commonly involved joints are the PIP, MCP, wrist and ankle joints. Progressive skin lesions can lead to flexion contractures of joints. Muscle weakness and fatigue symptoms are frequently seen symptoms. As well as myopathy caused by fibrosis in muscles may occur; polymyositis clinic may be added too. In addition, many organs, especially in genitourinary gasrointestinal tracts, can be involved in systemic sclerosis [14].
As a result; we should remind that plasma cell dyscrasia may induce erosive polyarthrit or olygoarthrit clinic,so immunogenetic process in arthritis clinic should be discloused. Our case of MM with symmetric erosive and seronegative inflammatory polyarthritis has been a guide between these two entity for us. Tos um up; in elderly atypical oligo/polyarthritis clinic should remind us for plasma cell dyscrasia.
References
1. Rajkmar SV. Multiple Myeloma: 2012 update on diagnosis, risk-stratification, and management, J. Heamatology, 2012, No.87(1), pp.78-88.
2. Jargessen C, Guerin B, Ferrari V. Arthritis assosiation with monoclonal gammopathy’s clinical characteristics, Br J Rheumol, 1996, No.35, pp.241-243.
3. Molley C., Peck R., Banry S. An unusual presentation of Multiple Myeloma: a case report, J. Med, 2007, No.1, pp.84-87.
4. Vitalli C, Baglioni P, Vivaldi I. Erosive arthritis in monoclonal gammopathy of unknown signifigance: report of four cases, Arthitis Rheum, 1991, No.34, pp.1600-1605.
5. Agorwal D, Sharma A, Kapoor S. Multiple Myeloma presenting with musculoskeletal manifestations: A case report, Int J Rheumon Dis, 2010, No.13(3), pp.242-245.
6. Wadhera RK, Kyle RA. Incidence, clinical course and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with Multiple Myeloma, Blood, 2011, No.118(11), pp.2985-2987.
7. Malley C., Pech R., Banry S. An unusual presentation of multiple myeloma: a case report, J Med, 2007, No.1, p.84.
8. Rado MS, Podor K, Breitkreuz I. MM Lancet. 2009, No.374(9686), pp.324-339.
9. Alpay N, Artim-Esen B, Kamali S. Amyloid artropathy mimicing seronegative rheumatoid arthritis in multiple myeloma: case reports and review of litherature, Amyloid, 2009, No.1614, pp.226-231.
10. Roca F, Lantant Weybel K. AL amyloidosis with myeloma mimicing rheumatoid arthritis, Joint Bone Spine, 2011, No.78(2), pp.215-216.
11. Hank H, Teitelbaum A, Kaura S. Evoluation of clinical benefit of long term (beyond 2 years) treatment of skeletal related
№2 (36) 2015 Clinical Medicine of Kazakhstan
37
events in advanced cancers with zolendronic acid, Curn. Med. Des. Opin, 2012, No.28(7), pp.1119-1127.
12. Morgan G.J. Effects of induction and maintenance plus long term bifosfonate on bone diseases in patients with multiple myeloma, Blood, 2012, No.119 (23), pp.5374-5383.
13. Schutz N, Marker-Herman E. Rheumoid Arthritis and MM as comorbidity. is Tocilizumab a therapy option? Z. Rheumatol, 2012, No.71(1), pp.78-82.
14. 14. Parades-Suarez C, Fernandez-Redendo V Multiple Myeloma with Scleroderma like changes, J Eur Acad Dermatol Venereol, 2005, No.19(4), pp.500-502.
38
№2 (36) 2015 Clinical Medicine of Kazakhstan
